Table 4.
General health outcomes
| Nifedipine (n = 115) | Atosiban (n = 110) | OR | 95% CI | P | |
|---|---|---|---|---|---|
| Hospital admissions (any) | 61/108 (57%) | 53/108 (49%) | 1.45 | 0.84–2.51 | 0.18 |
| Hospital admissions (≥3) | 14/108 (13%) | 6/108 (5.6%) | 3.18 | 1.05–9.66 | 0.041 |
| Surgery (any) | 38/110 (35%) | 38/109 (35%) | 1.03 | 0.58–1.84 | 0.92 |
| Surgery (≥3) | 8/110 (7.3%) | 6/109 (5.6%) | 1.54 | 0.48–4.90 | 0.47 |
| Any specialist visits | 91/112 (81%) | 84/108 (78%) | 1.47 | 0.72–3.00 | 0.29 |
| General practitioner | 65/112 (58%) | 64/107 (60%) | 0.98 | 0.55–1.76 | 0.96 |
| Developmental specialist | 55/110 (50 %) | 48/107 (50%) | 1.41 | 0.78–2.55 | 0.26 |
| Medical specialist | 79/112 (71%) | 70/108 (65%) | 1.43 | 0.76–2.68 | 0.27 |
| Medication use (ever) | 84/110 (76%) | 75/109 (69%) | 1.55 | 0.80–3.00 | 0.19 |
| Medication use (current) | 26/110 (24%) | 25/109 (23%) | 1.06 | 0.55–2.04 | 0.85 |